Abbott to start REPAIR MR clinical trial of MitraClip device for MR
Abbott has received the US Food and Drug Administration (FDA) approval for a clinical study of its minimally invasive MitraClip device in open heart mitral valve surgical repair.
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XAbbott has received the US Food and Drug Administration (FDA) approval for a clinical study of its minimally invasive MitraClip device in open heart mitral valve surgical repair.
US-based medical technology firm ADM Tronics Unlimited (ADMT) has signed an engineering development agreement with RetinalGeniX Technologies (RTI), to develop and manufacture the latter’s patented ophthalmic diagnostic technology,
Bigfoot Biomedical, Inc. announced today that the company has raised $45 million in the initial tranche of a Series C equity financing. The round is led by Abbott
A research team from Pohang University of Science and Technology (POSTECH) has developed a smart light-emitting diode (LED) contact lens and a wearable medical device for diabetics. Led
Scientists from the UK’s Institute of Cancer Research, along with researchers and clinicians from the Royal Marsden NHS Foundation Trust, have conducted a phase II clinical trial of
ArcherDX, Inc. today announced a non-exclusive, multi-year partnership with Illumina, Inc. (NASDAQ: ILMN) intended to broaden access of next generation sequencing (NGS)-based oncology testing, including companion diagnostics for
ProciseDx today announced the attainment of CE mark for its Procise CRP assay (C reactive protein) which is the first of its family of gastrointestinal markers. This follows
Medtronic has received the CE Mark approval for its Percept PC neurostimulator with BrainSense technology, for delivering therapy to patients with neurologic disorders. The Percept PC neurostimulator is
US-based biotechnology firm Element Biosciences has secured $80.3m in a Series B financing round, to advance the development of its low-cost genomic sequencing solutions. The funding round saw
Silver Bullet Therapeutics, Inc., a privately-held medical device company, announced today that it has received recommendation for CE Mark approval for the commercial sale of its antimicrobial OrthoFuzIon™